Navigation Links
CHERISH trial demonstrates efficacy of tocilizumab in juvenile idiopathic arthritis
Date:6/12/2013

Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA).

Tocilizumab is a humanized recombinant antibody, which blocks the receptors where interleukin-6 (IL-6) attaches to the surface of cells. When IL-6 is unable to attach to these cells, they are prevented from driving inflammation. Elevated serum and joint fluid IL-6 levels have been shown to be associated with disease activity in patients with pcJIA.1

"JIA is a chronic arthritis occurring in 1 in every 1,000 children. With no known cause, it can lead to joint damage and permanent disability. These data show that tocilizumab rapidly improves signs and symptoms of pcJIA, with meaningful clinical responses maintained in a large proportion of patients at week 40," said lead author Dr. Fabrizio De Benedetti of the IRCCS Ospedale Pediatrico Bambino Gesu, Rome.

Speaking on behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG), who had overseen this study, Dr. De Benedetti concluded that "these data suggest that tocilizumab is going to be a novel biologic part of the therapeutic armamentarium for pcJIA."

CHERISH is a two-year, 3-part trial being conducted at 58 centres across 15 countries. Patients aged 2-17 years were included in the study if they had active pcJIA for at least 6 months and had failed to respond to methotrexate (a cornerstone of therapy worldwide for this condition).

Part 1 of the study was a 16-week open-label phase in which 188 patients received tocilizumab every four weeks. The 166 patients who achieved at least a 30% improvement in symptoms and signs of pcJIA (an JIA ACR30* response) went on to part 2, which was a 24-week
'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Brain Tumor Vaccine Shows Promise in Early Trial
2. URMC clinical trial tests new regimen for hypertension
3. Analysis Finds Clinical Trials Often Small, of Poor Quality
4. US spends far more for health care than 12 industrialized nations, but quality varies
5. New Weight-Loss Drug Shows Promise in Trial
6. Palpitations are predictive of future atrial fibrillation
7. Trial Set to See if Drug Can Prevent Alzheimers
8. Experts call for clinical trials to test non-skeletal benefits of vitamin D
9. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
10. Canada should significantly increase its funding of randomized clinical trials
11. Alzheimers vaccine trial a success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 BuyCheapTicketsToEvents.com is ... wide selection of tickets to many events. Cheap NHL hockey ... begin in September. , Hockey fans are enthusiastic about their ... tickets for games. Now is the time to acquire 2014 ... in mere months. There will be a great deal of ...
(Date:8/20/2014)... people grow older, they often have difficulty falling asleep ... in the morning. In individuals with Alzheimer,s disease, this ... especially pronounced, often leading to nighttime confusion and wandering. ... Israel Deaconess Medical Center (BIDMC) and the University of ... more fragmented with age. Reported online today in the ...
(Date:8/20/2014)... Mixberry Media announced today its new integrated ... a new source of revenue. , The innovative experience ... a narration of their favorite news and articles using ... Users can now multitask: read/write email, drink coffee, get ... , Mixberry Media’s service converts news and ...
(Date:8/20/2014)... Riverside Health System is pleased to ... its Warsaw Medical Arts team earlier this year, bringing ... is accepting new patients. , Dameron, a 2009 graduate ... residency at the Mountain Area Health Education Center in ... really like the rural aspect of [Tappahannock],” Dameron said ...
(Date:8/19/2014)... As moms and dads prepare their children to go ... normal routine of dropping their little ones off at daycare ... encourages them to use the opportunity to implement a ... Yarker explains, “Kids have small tummies, short attention spans, and ... food handouts, use snack time as another daily opportunity to ...
Breaking Medicine News(10 mins):Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Riverside Warsaw Medical Arts’ Dr. William Dameron Accepting New Patients 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3
... , NEW YORK, Sept. 21 ... the validity of two Minerva Industries, Inc. patents for mobile ... of new evidence which can show Eli Lilly & Company,s ... counsel. The discovery of this patent validity evidence can impact ...
... , ST. LOUIS, Sept. 21 ... Perrigo Company (Nasdaq: PRGO ) of KV,s first-to-file Paragraph ... Drug Administration for a generic equivalent version of GlaxoSmithKline,s Duac(R) gel. ... transaction, KV will receive $14 million from Perrigo at closing and ...
... WASHINGTON, Sept. 21 /EIN News/ According to the Web site ... the Clinton administration Philip Morris "worked off-the-record with . . . ... have been partly funded by a huge increase in tobacco taxes. ... the term "death panels" used by anti-healthcare reform activists determined to ...
... By 2050, 115 million people may suffer from dementia ... Alzheimer,s disease is accelerating at a rapid pace, and by ... from dementia -- a 10 percent increase since 2005, ... double every 20 years, reaching 65.7 million in 2030 and ...
... , , FORT ... Multicultural Communities Survey sponsored by the LACTAID(R) Brand found that ... or dairy in their diet as a way to manage their ... have lactose intolerance worry the condition keeps them from consuming important ...
... , BALTIMORE, Sept. 21 A new ... the recession is contributing to acute, or short-term, physical pain ... Pain Awareness Month, 68 percent of people who experienced acute ... the past year said that the recession caused, increased or ...
Cached Medicine News:Health News:Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 2Health News:Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 3Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 2Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 3Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 4Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 5Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 6Health News:'Death Panel' Inventor & Critic of Healthcare Reform Betsy McCaughey 'Has Close Ties' to Philip Morris; Healthcare Industry Today Offers Complete Coverage 2Health News:Alzheimer's Soars, Global Focus Needed: Study 2Health News:Alzheimer's Soars, Global Focus Needed: Study 3Health News:New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 2Health News:New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 3Health News:New Research Finds Most African American Women with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 4Health News:Economic Pain Contributing to Acute Physical Pain for Many Americans, New Survey Says 2Health News:Economic Pain Contributing to Acute Physical Pain for Many Americans, New Survey Says 3Health News:Economic Pain Contributing to Acute Physical Pain for Many Americans, New Survey Says 4
(Date:8/19/2014)... 19, 2014  Boehringer Ingelheim today announced that ... for review the New Drug Application (NDA) for ... delivered via the Respimat ® inhaler for ... of airflow obstruction in patients with chronic obstructive ... Tiotropium + olodaterol FDC will not be indicated ...
(Date:8/19/2014)... -- Cardiva Medical, Inc. announced today that it has closed ... 3 private equity financing and a $12.5 million senior ... the proceeds of the Series 3 private equity financing ... VASCADE® Vascular Closure System in the United ... 3 private equity financing was a new investor, Canepa ...
(Date:8/19/2014)... Aug. 19, 2014  Sequence, Inc., an industry leader in ... and medical device manufacturers is opening a third office location ... , as a result of demand by clients to ... opened this month, allows Sequence to better serve new and ... St. Louis office provides Sequence a hub ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2Quality and Compliance Solutions Provider Announces Opening of St. Louis, Missouri Office 2
... FRANCISCO, Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, ... from ongoing clinical,studies of SNS-595 and SNS-032 at ... being held June 7-10, 2007 in Vienna,Austria. , ... Phase 1 clinical trial of SNS-595 in acute ...
... Zurich, June 1, 2007-Cytos Biotechnology AG is ... presentations of its novel,immunotherapeutic CYT003-QbG10 to treat ... were obtained,and will be presented in different ... Academy of Allergology and Clinical Immunology,(EAACI), taking ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007 2
... A lower cost alternative to Equalizers, the patented ... between two different vessel configurations. With the push ... be quickly and easily adjusted for test tubes ... Ergonomic Design for Unparalleled Comfort Pick one ...
... 384 Well Plate Capability The Equalizer ... original Equalizerexpandable and equal tip spacing, choice of ... capabilities. In addition, this model allows you to ... loading and accessing many gels and for use ...
... The Equalizer With 384 Well Plate Capability ... revolutionary features of the original Equalizerexpandable and equal ... components, and in-lab calibration capabilities. In addition, this ... down to 4.5mm for loading and accessing many ...
... Equally Spaced, Expandable, Multichannel Pipettor ... pipettors and instantly boosts productivity with an ... the simple adjustment of a slide rod. ... transfer of liquids between vessels with different ...
Medicine Products: